Literature DB >> 29197114

The correlation between SNPs within the gene of adrenergic receptor and neuropeptide Y and risk of cervical vertigo.

Jianlong Han1,2, Jinliang Zuo2, Dengsong Zhu2, Chunzheng Gao1.   

Abstract

BACKGROUND: The current investigation was aimed to explore the potential associations of SNPs within ADRB2, ADRB1, NPY, and ADRA1A with risk and prognosis of cervical vertigo.
METHODS: Altogether 216 patients with cervical vertigo and 204 healthy controls were gathered, and their DNAs were extracted utilizing the whole-blood DNA extraction kit. Besides, the PCR reactions were conducted using the TaqManR single nucleotide polymorphism (SNP) genotyping assays, and the SNPs were detected on the 7900HT real-time fluorogenic quantitative polymerase chain reaction (PCR) instrument. Finally, the severity of cervical vertigo was classified according to the JOA scoring, and the recovery rate (RR) of cervical vertigo was calculated in light of the formula as: [Formula: see text]
RESULTS: The SNPs within ADRA1A [rs1048101 (T>C) and rs3802241 (C>T)], NPY [rs16476 (A>C), rs16148 (T>C), and rs5574 (C>T)], ADRB1 [rs28365031 (A>G)] and ADRB2 [rs2053044 (A>G)] were all significantly associated with regulated risk of cervical vertigo (all P < .05). Haplotypes of ADRA1A [CT and TC] and NPY [CCT and ATT] were also suggested as the susceptible factors of cervical vertigo in comparison with other haplotypes. Furthermore, the SNPs within ADRA1A [rs1048101 (T>C)], NPY [rs16476 (A>C), rs16148 (T>C)], as well as ADRB1 [rs28365031 (A>G)] all appeared to predict the prognosis of cervical vertigo in a relatively accurate way (all P < .05). Ultimately, the haplotypes of ADRA1A (CC) and NPY (CCT) tended to decrease the RR.
CONCLUSIONS: The SNPs within ADRB2, ADRB1, NPY, and ADRA1A might act as the diagnostic biomarkers and treatment targets for cervical vertigo.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990ADRA1Azzm321990; zzm321990ADRB1zzm321990; zzm321990ADRB2zzm321990; zzm321990NPYzzm321990; Cervical vertigo; SNP; prognosis; risk

Mesh:

Substances:

Year:  2017        PMID: 29197114      PMCID: PMC6817151          DOI: 10.1002/jcla.22366

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese population.

Authors:  Tetsuro Matsunaga; Koichiro Yasuda; Tetsuya Adachi; Ning Gu; Tsubasa Yamamura; Toshio Moritani; Gozoh Tsujimoto; Kinsuke Tsuda
Journal:  J Hum Genet       Date:  2006-10-31       Impact factor: 3.172

2.  Alpha 1-adrenergic receptor antibodies in patients with primary hypertension.

Authors:  H P Luther; V Homuth; G Wallukat
Journal:  Hypertension       Date:  1997-02       Impact factor: 10.190

3.  Repositioning chairs in benign paroxysmal positional vertigo: implications and clinical outcome.

Authors:  Niels West; Søren Hansen; Martin Nue Møller; Sune Land Bloch; Mads Klokker
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-07       Impact factor: 2.503

4.  Alpha- and beta-adrenergic receptor polymorphisms in hypertensive and normotensive offspring.

Authors:  Massimo Iacoviello; Cinzia Forleo; Sandro Sorrentino; Roberta Romito; Elisabetta De Tommasi; Katya Lucarelli; Pietro Guida; Maria Vittoria Pitzalis
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-05       Impact factor: 2.160

5.  Functional evidence for the differential control of superficial and deep blood vessels by sympathetic vasoconstrictor and primary afferent vasodilator fibres in rat hairless skin.

Authors:  H J Häbler; J U Stegmann; L Timmermann; W Jänig
Journal:  Exp Brain Res       Date:  1998-01       Impact factor: 1.972

6.  An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events.

Authors:  A Snapir; P Heinonen; T P Tuomainen; P Alhopuro; M K Karvonen; T A Lakka; K Nyyssönen; R Salonen; J Kauhanen; V P Valkonen; U Pesonen; M Koulu; M Scheinin; J T Salonen
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

7.  Insertion/deletion polymorphism in alpha2-adrenergic receptor gene is a genetic risk factor for sudden cardiac death.

Authors:  Jari A Laukkanen; Timo H Mäkikallio; Jussi Kauhanen; Sudhir Kurl
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

8.  Plasma neuropeptide Y and catecholamines in women and men with essential hypertension.

Authors:  B Wocial; H Ignatowska-Switalska; P Pruszczyk; P Jedrusik; A Januszewicz; M Lapinski; W Januszewicz; Z Zukowska-Grojec
Journal:  Blood Press       Date:  1995-05       Impact factor: 2.835

Review 9.  Modulation of neuropeptide Y receptors for the treatment of obesity.

Authors:  Nagaaki Sato; Yoshio Ogino; Satoshi Mashiko; Makoto Ando
Journal:  Expert Opin Ther Pat       Date:  2009-10       Impact factor: 6.674

10.  Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension.

Authors:  M L Fu; H Herlitz; G Wallukat; E Hilme; T Hedner; J Hoebeke; A Hjalmarson
Journal:  Lancet       Date:  1994-12-17       Impact factor: 79.321

View more
  2 in total

1.  Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients.

Authors:  Annika M A Berends; Mathieu S Bolhuis; Ilja M Nolte; Edward Buitenwerf; Thera P Links; Henri J L M Timmers; Richard A Feelders; Elisabeth M W Eekhoff; Eleonora P M Corssmit; Peter H Bisschop; Harm R Haak; Ron H N van Schaik; Samira El Bouazzaoui; Bob Wilffert; Michiel N Kerstens
Journal:  Biomedicines       Date:  2022-04-13

2.  Neuropeptide Y upregulates Runx2 and osterix and enhances osteogenesis in mouse MC3T3‑E1 cells via an autocrine mechanism.

Authors:  Bo Zhang; Xiaolei Zhang; Juan Xiao; Xuguang Zhou; Yuan Chen; Chunzheng Gao
Journal:  Mol Med Rep       Date:  2020-09-14       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.